Brian Lin
Editorial Director at EurekAlert!
@EurekAlert editorial director, lover of #arts, #scicomm and #DEI, RT's aren't endorsements. All views are my own. 🏳️🌈
Articles
-
3 weeks ago |
nature.com | Brian Lin |Atharva Bhagwat |Isha Monga |Ke Xu |Danielle Dionne |Peiwen Cai | +5 more
AbstractHuman airways contain specialized rare epithelial cells including CFTR-rich ionocytes that regulate airway surface physiology and chemosensory tuft cells that produce asthma-associated inflammatory mediators. Here, using a lung cell atlas of 311,748 single cell RNA-Seq profiles, we identify 687 ionocytes (0.45%). In contrast to prior reports claiming a lack of ionocytes in the small airways, we demonstrate that ionocytes are present in small and large airways in similar proportions.
Advancing ALS Through Gene Therapies, Early Intervention, and Multidisciplinary Care: Brian Lin, PhD
1 month ago |
neurologylive.com | Isabella Ciccone |Brian Lin
CommentaryVideoMay 15, 2025Author(s):,Fact checked by:The research portfolio director at the Muscular Dystrophy Association discussed the evolving ALS therapeutic landscape, highlighting advances in genetic and RNA-based interventions.
-
1 month ago |
neurologylive.com | Isabella Ciccone |Brian Lin
Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and fatal neurodegenerative disease with limited therapeutic options for patients living with the condition. One of the major challenges for the ALS field has been the incomplete understanding of the disease’s underlying biology, which has restricted the ability to target upstream mechanisms.
-
1 month ago |
medicalxpress.com | Brian Lin
Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball player—is a progressive neurodegenerative disease that affects thousands of Americans every year. ALS remains one of the most complex and challenging disorders known to science.
-
1 month ago |
neurologylive.com | Isabella Ciccone |Brian Lin
WATCH TIME: 3 minutes“I think everyone in the field is really looking forward to seeing if some of the other genetically targeted therapies that are in the pipeline are going to be as successful as tofersen. We should really see those results coming up pretty soon.”Recent progress in gene and RNA-targeted therapies has possibly reshaped the therapeutic landscape for amyotrophic lateral sclerosis (ALS), particularly for patients with known genetic mutations.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 4K
- DMs Open
- Yes
Reaching back into my @UBC #mediarelations days for some golden nuggets in this new @EurekAlert blogpost on creating a multi-faceted #scicomm campaign.
Want to discover how to leverage @EurekAlert!’s diverse content types to develop a comprehensive #SciComm campaign?🌟 Read our latest blogpost here: https://t.co/i63jjPa0ts 1/6 #MarketingTips #ContentStrategy https://t.co/lVePYA9EJi
RT @EurekAlert: Want to discover how to leverage @EurekAlert!’s diverse content types to develop a comprehensive #SciComm campaign?🌟 Read o…
RT @LuzSpica: Aprendí y repasé mucho esta mañana en el taller que impartieron @brianlinworks, @lecteroide, @ggonzalitos y @ElAgusdeKomodo.…
